BENLYSTA (Human Genome Sciences, Inc.)
Welcome to the PulseAid listing for the BENLYSTA drug offered from Human Genome Sciences, Inc.. This Decreased B Lymphocyte Activation [PE],B Lymphocyte Stimulator-specific Inhibitor [EPC],B Lymphocyte Stimulator-directed Antibody Interactions [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Human Genome Sciences, Inc. |
NON-PROPRIETARY NAME: | belimumab |
SUBSTANCE NAME: | BELIMUMAB |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Decreased B Lymphocyte Activation [PE],B Lymphocyte Stimulator-specific Inhibitor [EPC],B Lymphocyte Stimulator-directed Antibody Interactions [MoA] |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 2011-03-10 |
END MARKETING DATE: | 0000-00-00 |
BENLYSTA HUMAN PRESCRIPTION DRUG Details:
Item Description | BENLYSTA from Human Genome Sciences, Inc. |
LABELER NAME: | Human Genome Sciences, Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 120(mg/1.5mL) |
START MARKETING DATE: | 2011-03-10 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 49401-101_bdb3042f-a604-455a-bbd3-d263a9130c75 |
PRODUCT NDC: | 49401-101 |
APPLICATION NUMBER: | BLA125370 |
Other BELIMUMAB Pharmaceutical Manufacturers / Labelers: